Initiated in 2011 by the EurocanPlatform and since 2016 organized under the umbrella of Cancer Core Europe, the Summer School in Translational Cancer Research will once again take place in Portugal in Albufeira, 16 – 20 October, 2017. The registration deadline is 30 June 2017. You can learn more about the course here: https://dktk.dkfz.de/en/training/dktk-summer-school/introdution.
This author has yet to write their bio.Meanwhile lets just say that we are proud mercuric contributed a whooping 33 entries.
Entries by mercuric
Applications are now being accepted for the third EUPATI Expert Training Course. The EUPATI Training Course Patient Experts in Medicines Research & Development is an exciting and unique opportunity offering patient advocates expert-level training in medicines research and development, specifically tailored for them. The application deadline is 31 March 2017.
Congratulations to Margaret Grayson, our MErCuRIC Patient Representative, who received a ‘Special Commendation’ for Research Engagement from Cancer Research UK in 2016!
The MErCuRIC team met at UZA in Antwerp for our Year 3 meeting (05 – 06 Dec 2016). We discussed progress in the Phase I trial from the previous year, and mapped our clinical and translational activities for the coming year. As the dose escalation phase I study draws to a close, we are planning […]
The latest newsletter from EUPATI is now available. This issue covers an update on national activities across Europe and metrics on use of the EUPATI website.
MErCuRIC results were presented in a poster at the NCRI Cancer Conference in Liverpool, UK on 08 Nov 2016 (Session B, 08:15-11:00). The conference ‘showcases the latest basic, translational and clinical cancer research. It brings researchers together to share ideas and develop collaborations.’ ‘MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced […]
The latest newsletter from EUPATI is now available. This issue covers an update on national activities in 18 countries and information on the upcoming EUPATI 2016 conference All Aboard to a Better Health Future on 14 Dec 2016.
The MErCuRIC Phase I trial was presented at the ESMO 2016 Congress in Copenhagen (7 – 11 Oct 2016). MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours (Poster: 480P) R. Wilson, M. Middleton, J. Houlden, S. Van Schaeybroeck, C. Rolfo, E. Elez, J. Taieb , […]
Technologies to isolate and analyse liquid biopsy samples are rapidly evolving. MErCuRIC researcher Federica Di Nicolantonio discusses the technique in this video produced with ESMO.
The summer 2016 newsletter for the European Patients’ Academy (EUPATI) is now available. In this issue, you can access the Patient Expert Training Course, now available in English, as well as learn about the growing national EUPATI teams that function as patient involvement groups locally.
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.